American Trust’s Repligen RGEN Stock Holding History

American Trust’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,100	Closed	-$243K	–	474
2022 Q3	$243K	Buy	+1,100	New	+$232K	0.02%	332

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

American Trust's RGEN Position: Q4 2022 in Review

American Trust sold out of Repligen (RGEN) in Q4 2022, closing a stake of 1,100 shares — an estimated $243K sold.

American Trust first reported a position in RGEN in Q3 2022 and held it in 1 quarter. The position peaked at $243K in Q3 2022. 441 funds tracked by Wall St. Rank hold RGEN as of Q4 2022.

American Trust reported no remaining Repligen position as of Q4 2022 after selling out during the quarter.
American Trust sold 1,100 Repligen shares in Q4 2022, an estimated $243K.
American Trust first reported a position in Repligen in Q3 2022 and held it in 1 quarter.
American Trust's Repligen position peaked at $243K in Q3 2022.
441 funds tracked by Wall St. Rank held Repligen as of Q4 2022.

Based on American Trust's 13F filing for Q4 2022, filed 16 Feb 2023.